Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
degree increased » hygiene increased (Expand Search), age increased (Expand Search), center increased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
degree increased » hygiene increased (Expand Search), age increased (Expand Search), center increased (Expand Search)
-
701
-
702
-
703
Melting curves.
Published 2025“…Elevated OIP5-AS1 expression was associated with an increased incidence of apoptosis. The silencing of OIP5-AS1 in I/R conditions resulted in a significant suppression of cell apoptosis, reduced cleavage of caspase-3, decreased Bax levels, and increased Bcl-2 levels. …”
-
704
Original blot and gel image data.
Published 2025“…Elevated OIP5-AS1 expression was associated with an increased incidence of apoptosis. The silencing of OIP5-AS1 in I/R conditions resulted in a significant suppression of cell apoptosis, reduced cleavage of caspase-3, decreased Bax levels, and increased Bcl-2 levels. …”
-
705
Transfection sequences.
Published 2025“…Elevated OIP5-AS1 expression was associated with an increased incidence of apoptosis. The silencing of OIP5-AS1 in I/R conditions resulted in a significant suppression of cell apoptosis, reduced cleavage of caspase-3, decreased Bax levels, and increased Bcl-2 levels. …”
-
706
Experimental data.
Published 2025“…Elevated OIP5-AS1 expression was associated with an increased incidence of apoptosis. The silencing of OIP5-AS1 in I/R conditions resulted in a significant suppression of cell apoptosis, reduced cleavage of caspase-3, decreased Bax levels, and increased Bcl-2 levels. …”
-
707
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
708
-
709
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
710
-
711
-
712
-
713
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
714
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
715
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
716
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
717
-
718
-
719
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
720